公开(公告)号：US08343943B2

公开(公告)日：2013-01-01

申请号：US12438914

申请日：2006-12-06

Applicant: Soo Youl Kim ,  Dae Seok Kim

Inventor： Soo Youl Kim ,  Dae Seok Kim

IPC: A01N43/04 ,  A01N43/16 ,  A61K31/70 ,  A61K31/35 ,  C07D315/00

CPC classification number: A61K31/35 ,  A61K31/7028 ,  A61K31/704 ,  A61K2300/00

Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.

Abstract translation: 本文公开了包含葡糖胺，葡糖胺衍生物或其盐的癌敏化剂。 当向癌症患者施用时，癌症敏化剂用于使癌细胞对抗癌剂敏感而不产生副作用，从而提高化疗的治疗效率。

公开(公告)号：US20110288176A1

公开(公告)日：2011-11-24

申请号：US12920406

申请日：2009-11-27

Applicant: Soo Youl Kim ,  Chang Hoon Lee ,  Byung Il Lee ,  Kyung Chae Jeong

Inventor： Soo Youl Kim ,  Chang Hoon Lee ,  Byung Il Lee ,  Kyung Chae Jeong

IPC: A61K31/192 ,  A61P35/00 ,  A61P25/00 ,  C12N9/99 ,  A61P19/02 ,  A61P37/06 ,  A61P25/28 ,  A61P25/16 ,  A61P29/00 ,  A61P35/04

CPC classification number: A61K31/192

Abstract: The present invention relates to ethacrynic acid and a transglutaminase inhibitor comprising a pharmaceutically acceptable salt of ethacrynic acid; more particularly, to ethacrynic acid for inhibiting the activity of transglutaminase involved in the pathogenesis of diseases in cases of altered expression, a transglutaminase inhibitor comprising a pharmaceutically acceptable salt of ethacrynic acid, and to a novel use of thereof. According to the present invention, there are provided ethacrynic acid, a transglutaminase inhibitor comprising active components of a pharmaceutically acceptable salt of ethacrynic acid and a transglutaminase inhibition method. The present ethacrynic acid, transglutaminase inhibitor comprising a pharmaceutically acceptable salt of ethacrynic acid or ethacrynic acid itself, and transglutaminase inhibition method provide a safer application without side effects to a patient having a disease where altered expression of transglutaminase is observed, thereby providing the inhibitory effect on transglutaminase.

Abstract translation: 本发明涉及含有柠檬酸的药学上可接受的盐酸和转谷氨酰胺酶抑制剂， 更具体地，涉及用于抑制参与改变表达的疾病发病机理中的转谷氨酰胺酶的活性的乙酰丙酸，包含其药学上可接受的盐酸的转谷氨酰胺酶抑制剂及其新用途。 根据本发明，提供了乙酸，谷氨酸，转谷氨酰胺酶抑制剂，其包含药学上可接受的盐酸的活性成分和转谷氨酰胺酶抑制方法。 本发明的乙酰丙酸，转谷氨酰胺酶抑制剂本身含有药学上可接受的盐酸或乙酰丙酸，以及转谷氨酰胺酶抑制方法提供了对具有观察到转谷氨酰胺酶表达改变的疾病的患者没有副作用的更安全的应用，从而提供抑制作用 转谷氨酰胺酶。

公开(公告)号：US20130164813A1

公开(公告)日：2013-06-27

申请号：US13334432

申请日：2011-12-22

Applicant: Young Dae Gong ,  Soo Youl Kim

Inventor： Young Dae Gong ,  Soo Youl Kim

IPC: C12N9/99

CPC classification number: C12Y203/02013 ,  A61K31/4985 ,  C12N9/1044

Abstract: The present invention relates to a method for inhibiting transglutaminase 2 activity using 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivatives.

Abstract translation: 本发明涉及使用2-烷氧基-3-苯基乙炔基-4a，5-二氢吡啶并[2,3-b]吡嗪衍生物来抑制转谷氨酰胺酶2活性的方法。

公开(公告)号：US20120156137A1

公开(公告)日：2012-06-21

申请号：US12446238

申请日：2007-10-19

Applicant: Soo-youl Kim ,  Chang-hoon Lee ,  Ai-young Lee

Inventor： Soo-youl Kim ,  Chang-hoon Lee ,  Ai-young Lee

IPC: A61K31/7008 ,  A61P17/00 ,  C12Q1/52 ,  C07H5/06 ,  A61K49/00

CPC classification number: A61K31/7028

Abstract: Disclosed herein is a novel use of glucosamine or a derivative thereof. A pharmaceutical composition for treating atopic dermatitis comprising glucosamine or a derivative thereof and a method of treating atopic dermatitis using the composition are disclosed. The pharmaceutical composition and the method realize the safe treatment of atopic dermatitis without the side effects associated with conventional anti-inflammatory drugs.

Abstract translation: 本文公开了葡糖胺或其衍生物的新用途。 公开了包含葡糖胺或其衍生物的治疗特应性皮炎的药物组合物和使用该组合物治疗特应性皮炎的方法。 药物组合物和方法实现了与常规抗炎药相关的副作用的特应性皮炎的安全治疗。

公开(公告)号：US20100323033A1

公开(公告)日：2010-12-23

申请号：US12740978

申请日：2008-10-01

Applicant: Soo Youl Kim ,  Kang-Seo Park ,  Kyung chae Jeong

Inventor： Soo Youl Kim ,  Kang-Seo Park ,  Kyung chae Jeong

IPC: A61K33/24 ,  C07C69/732 ,  A61K31/225 ,  A61K31/675 ,  A61K31/282 ,  A61K31/704 ,  A61K31/351 ,  A61K38/14 ,  A61K31/437 ,  A61K31/475 ,  A61K31/337 ,  A61K31/7048 ,  A61K31/7028 ,  A61K31/255 ,  A61K31/407 ,  A61K31/381 ,  A61P35/00

CPC classification number: A61K31/216

Abstract: The present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof. In particular, the present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof, which can make cancer cells sensitive to anticancer agents to increase the therapeutic effect of anticancer agents. In addition, the present invention relates to a composition for inhibiting the chemo-resistance of cancer cells, comprising chlorogenic acid or a derivative thereof in combination with a pharmaceutically acceptable carrier, an anticancer composition comprising an anticancer agent in addition to the composition, and a method for disrupting the chemo-resistance of cancer cells, comprising administration of the cancer sensitizer.

Abstract translation: 本发明涉及包含绿原酸或其衍生物的癌症敏化剂。 特别地，本发明涉及包含绿原酸或其衍生物的癌症敏化剂，其可以使癌细胞对抗癌剂敏感，以增加抗癌剂的治疗效果。 此外，本发明涉及一种抑制癌细胞的化学抗性的组合物，其包含与药学上可接受的载体组合的绿原酸或其衍生物，除了该组合物之外还含有抗癌剂的抗癌组合物和 用于破坏癌细胞的化学抗性的方法，包括施用所述癌症敏化剂。

公开(公告)号：US20100016249A1

公开(公告)日：2010-01-21

申请号：US12438914

申请日：2006-12-06

Applicant: Soo Youl Kim ,  Dae Seok Kim

Inventor： Soo Youl Kim ,  Dae Seok Kim

IPC: A61K31/704 ,  C07D309/10 ,  A61K31/35 ,  A61P35/04

CPC classification number: A61K31/35 ,  A61K31/7028 ,  A61K31/704 ,  A61K2300/00

Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.

Abstract translation: 本文公开了包含葡糖胺，葡糖胺衍生物或其盐的癌敏化剂。 当向癌症患者施用时，癌症敏化剂用于使癌细胞对抗癌剂敏感而不产生副作用，从而提高化疗的治疗效率。

公开(公告)号：US20090197812A1

公开(公告)日：2009-08-06

申请号：US11918340

申请日：2006-10-11

Applicant: Soo youl Kim ,  In hoo Kim ,  Sung soo Park

Inventor： Soo youl Kim ,  In hoo Kim ,  Sung soo Park

IPC: A61K38/08 ,  C07K7/06 ,  C12N9/99

CPC classification number: C12N9/1044 ,  A61K38/00 ,  C07K14/4705

Abstract: Disclosed herein are transglutaminase peptide inhibitors which have inhibitory activity against transglutaminase, and a pharmaceutical composition comprising one of them as an active ingredient. The inhibitors or the composition is useful in the prevention and treatment of various diseases caused by aberrant transglutaminase activation, including inflammatory diseases and cancers. Also, methods for treating various inflammatory diseases and cancers and for preparing mutant peptides capable of inhibiting transglutaminase are also disclosed.

Abstract translation: 本文公开了对转谷氨酰胺酶具有抑制活性的转谷氨酰胺酶抑制剂和包含其中之一作为活性成分的药物组合物。 抑制剂或组合物可用于预防和治疗由异常转谷氨酰胺酶活化引起的各种疾病，包括炎性疾病和癌症。 此外，还公开了治疗各种炎性疾病和癌症以及制备能够抑制转谷氨酰胺酶的突变型肽的方法。

公开(公告)号：US20090029943A1

公开(公告)日：2009-01-29

申请号：US11918339

申请日：2006-06-23

Applicant: Soo youl Kim

Inventor： Soo youl Kim

IPC: A61K31/70 ,  C07H5/06 ,  A61P25/00 ,  C12N9/99

CPC classification number: A61K31/715

Abstract: Disclosed herein is a transglutaminase inhibitor comprising glucosamine or a derivative thereof. Exhibiting potent inhibitory activity against transglutaminase, the overexpression of which is responsible for the etiology of various diseases, glucosamine or derivatives thereof can be useful in the prevention and treatment of such diseases. Also, a pharmaceutical composition comprising glucosamine or a derivative thereof as an active ingredient and a method of inhibiting transglutaminase are disclosed. Featuring the use of the pharmaceutical composition, the method can be therapeutically safely and effectively-applied to patients afflicted with such diseases.

Abstract translation: 本文公开了包含葡糖胺或其衍生物的转谷氨酰胺酶抑制剂。 表现出对转谷氨酰胺酶的有效抑制活性，其过表达导致各种疾病的病因，葡糖胺或其衍生物可用于预防和治疗这些疾病。 此外，公开了包含葡糖胺或其衍生物作为活性成分的药物组合物和抑制转谷氨酰胺酶的方法。 通过使用药物组合物，该方法可以安全有效地应用于患有这些疾病的患者。

公开(公告)号：US08754033B2

公开(公告)日：2014-06-17

申请号：US11918340

申请日：2006-10-11

Applicant: Soo youl Kim ,  In hoo Kim ,  Sung soo Park

Inventor： Soo youl Kim ,  In hoo Kim ,  Sung soo Park

IPC: A61K38/00 ,  C12Q1/00 ,  C12N9/00 ,  C12N9/99 ,  C12N1/20 ,  C12N15/00 ,  C07H21/04

CPC classification number: C12N9/1044 ,  A61K38/00 ,  C07K14/4705

Abstract: Disclosed herein are transglutaminase peptide inhibitors which have inhibitory activity against transglutaminase, and a pharmaceutical composition comprising one of them as an active ingredient. The inhibitors or the composition is useful in the prevention and treatment of various diseases caused by aberrant transglutaminase activation, including inflammatory diseases and cancers. Also, methods for treating various inflammatory diseases and cancers and for preparing mutant peptides capable of inhibiting transglutaminase are also disclosed.

Abstract translation: 本文公开了对转谷氨酰胺酶具有抑制活性的转谷氨酰胺酶抑制剂和包含其中之一作为活性成分的药物组合物。 抑制剂或组合物可用于预防和治疗由异常转谷氨酰胺酶活化引起的各种疾病，包括炎性疾病和癌症。 此外，还公开了治疗各种炎性疾病和癌症以及制备能够抑制转谷氨酰胺酶的突变型肽的方法。

公开(公告)号：US20100173990A1

公开(公告)日：2010-07-08

申请号：US12663348

申请日：2008-06-11

Applicant: Soo Youl Kim ,  Kyung Chae Jeong

Inventor： Soo Youl Kim ,  Kyung Chae Jeong

IPC: A61K31/216 ,  C07C69/732 ,  A61P35/00 ,  A61P25/28 ,  A61P25/16

CPC classification number: A61K31/216

Abstract: The present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof. More particularly, the present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof which effectively inhibits the activity of transglutaminase, the overexpression of which is responsible for the etiology of various diseases, and to novel uses thereof. The present invention provides a transglutaminase inhibitor and a method of inhibiting transglutaminase, both of which are based on using chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient. Featuring the use of chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof, the novel method of inhibiting transglutaminase according to the present invention is safely applied to patients who suffer from the diseases caused by the overexpression of transglutaminase, thereby obtaining an inhibitory effect against transglutaminase without causing side-effects.

Abstract translation: 本发明涉及包含绿原酸的转谷氨酰胺酶抑制剂，其药学上可接受的盐或其衍生物。 更具体地说，本发明涉及一种转谷氨酰胺酶抑制剂，其包含绿原酸，其药学上可接受的盐或其衍生物，其有效抑制转谷氨酰胺酶的活性，其过表达导致各种疾病的病因和新用途 其中。 本发明提供了一种转谷氨酰胺酶抑制剂和抑制转谷氨酰胺酶的方法，两者均基于使用绿原酸，其药学上可接受的盐或其衍生物作为活性成分。 使用绿原酸，其药学上可接受的盐或其衍生物，根据本发明的抑制转谷氨酰胺酶的新方法被安全地应用于患有由转谷氨酰胺酶过表达引起的疾病的患者，从而获得抑制性 对转谷氨酰胺酶的作用不会引起副作用。